1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Asthma-Pipeline Insights, 2016

Chronic Asthma-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Chronic Asthma-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Chronic Asthma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Chronic Asthma. DelveInsight’s Report also assesses the Chronic Asthma therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Chronic Asthma
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Chronic Asthma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Chronic Asthma and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Chronic Asthma-Pipeline Insights, 2016

Illustrative Table of contents

- Chronic Asthma Overview
- Chronic Asthma Pipeline Therapeutics
- Chronic Asthma Therapeutics under Development by Companies
- Chronic Asthma Filed and Phase III Products
- Comparative Analysis
- Chronic Asthma Phase II Products
- Comparative Analysis
- Chronic Asthma Phase I and IND Filed Products
- Comparative Analysis
- Chronic Asthma Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Chronic Asthma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chronic Asthma - Discontinued Products
- Chronic Asthma - Dormant Products
- Companies Involved in Therapeutics Development for Chronic Asthma
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Chronic Asthma, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Chronic Asthma Assessment by Monotherapy Products
- Chronic Asthma Assessment by Combination Products
- Chronic Asthma Assessment by Route of Administration
- Chronic Asthma Assessment by Stage and Route of Administration
- Chronic Asthma Assessment by Molecule Type
- Chronic Asthma Assessment by Stage and Molecule Type
- Chronic Asthma Therapeutics - Discontinued Products
- Chronic Asthma Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Chronic Asthma, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Chronic Asthma Assessment by Monotherapy Products
- Chronic Asthma Assessment by Combination Products
- Chronic Asthma Assessment by Route of Administration
- Chronic Asthma Assessment by Stage and Route of Administration
- Chronic Asthma Assessment by Molecule Type
- Chronic Asthma Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Epiomic Epidemiology Series: Asthma Forecast in 8 Major Markets 2016-2026

Epiomic Epidemiology Series: Asthma Forecast in 8 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • August 2016
  • by Black Swan Analysis Ltd132

Asthma is a chronic disease involving airway inflammation, reversible airflow obstruction, and bronchial hyper-responsiveness. The condition is usually triggered by environmental factors of which the symptoms ...

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

  • $ 4995
  • Industry report
  • August 2016
  • by GBI Research

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way Summary The respiratory therapy ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.